Metered Inhaler Valve Coating for Low-Propellant Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing inhalers release a large amount of hydrofluorocarbon propellant, contributing to environmental harm and dose variability due to albuterol sticking to the valve, and there is a need to reduce the inhaler's mass while maintaining dose count.
Innovation Solution
Incorporating a valve with a volume of no more than 40 microliters coated with a two-layer coating, comprising a silane with reactive silane groups and a partially fluorinated compound, to prevent albuterol sticking and reduce propellant use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If a larger valve volume is used, then the propellant release per actuation is sufficient, but the environmental harm and global warming contribution increase
Solution Approach 1:
The patent changes the valve volume parameter from conventional larger sizes to a specific range of 5-40 μL, optimizing the propellant release quantity to minimize environmental impact while maintaining sufficient drug delivery. This parameter optimization directly addresses the contradiction by finding the minimum necessary propellant volume that still achieves therapeutic effect.
Solution Approach 2:
The patent applies a dual-layer coating system specifically on the valve components (valve stem, valve diaphragm, valve seat) rather than the entire inhaler. The coating creates a localized non-stick surface that prevents albuterol adhesion at the critical valve interface, allowing reduced propellant volumes to function effectively without the coating interfering with other inhaler components.
2Productivity
If albuterol concentration is increased in the canister, then the dose count is maintained, but albuterol sticks to the valve causing dose variability and valve damage
Solution Approach 1:
The patent introduces a dual-layer coating system as an intermediary substance between the albuterol formulation and the valve components. The first layer (silane-based) provides chemical bonding to the valve surface, while the second layer (fluorinated compound) provides a non-stick surface that prevents albuterol adhesion. This intermediary coating allows high concentration formulations to be used without causing valve sticking or dose variability.
Solution Approach 2:
The patent employs a composite coating structure consisting of two distinct layers with different functional properties. The first layer uses silane compounds for surface bonding, and the second layer uses fluorinated compounds for non-stick properties. This composite material approach combines the advantages of both materials to achieve both adhesion to the valve and prevention of albuterol sticking, enabling reliable high-dose formulations.
3Weight of moving object
If the inhaler mass is reduced, then shipping cost and environmental impact decrease, but the canister and component sizes must be minimized
Solution Approach 1:
The patent optimizes the valve volume parameter to 5-40 μL, which is significantly smaller than conventional valves. This parameter change enables a compact canister design that reduces overall inhaler mass while maintaining sufficient propellant volume for the required dose count. The small valve size directly contributes to weight reduction without compromising functionality.
Solution Approach 2:
The patent applies the dual-layer coating to valve components during manufacturing before final assembly. This preliminary coating action ensures that the non-stick surface is established on all valve surfaces that will contact the albuterol formulation, preventing sticking issues that would require larger safety margins in component design. The pre-applied coating allows for optimized, minimized component dimensions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution minimizes propellant release, reduces dose-to-dose variation, and allows for a smaller inhaler design without compromising dose count.
Implementation Method 1
The first layer comprises a silane with reactive silane groups
Implementation Method 2
The second layer comprises a partially fluorinated compound
Data Source
AI summary
An inhaler comprising a valve having a valve volume of no more than 40 micro liters and a valve having a first layer comprising a silane and a second layer comprising a polyfluoropolyether silane - and albuterol.